Company intelligence / Profile preview

Apica Cardiovascular

Ownership: Private
Development stage: Commercial

Overview

The ASC system demonstrated a high technical success rate and no major complications at the end of clinical trials, leading to CE Mark approval. The VAD SIS was under development to enable less invasive ventricular assist device implantation but had not reached human trials by the time of acquisition.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Apica Cardiovascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apica Cardiovascular.

Explore the full profile